DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Calcimimetic
Calcimimetic
Calcimimetic Use in Dialysis-Dependent
Effects of the Calcimimetic Cinacalcet Hcl on Cardiovascular Disease, Fracture, and Health-Related Quality of Life in Secondary Hyperparathyroidism
208325Orig1s000
Successful Reversal of Furosemide-Induced Secondary Hyperparathyroidism with Cinacalcet Tarak Srivastava, Shahryar Jafri, William E
Management of Renal Bone Disease
NATIONAL PBM BULLETIN December 26, 2017
Activation of the Calcium Receptor by a Calcimimetic Compound Halts the Progression of Secondary Hyperparathyroidism in Uremic Rats
FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment in More Than a Decade for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis
Calcimimetic Agents for the Treatment of Secondary Hyperparathyroidism William G
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
Osteoporosis in Patients with Chronic Kidney Diseases: a Systemic Review
Product Monograph
Sensipar (Cinacalcet) Tablets
Development and Psychometric Validation of the Nausea/Vomiting
Calcimimetic Use in Dialysis-Dependent Medicare Fee-For-Service Beneficiaries and Implications for Bundled Payment
Renal Osteodystrophy with Special Emphasis on Secondary Hyperparathyroidism
The Calcimimetic AMG 073 Reduces Parathyroid Hormone and Calcium X Phosphorus in Secondary Hyperparathyroidism
Calcimimetic Agents: Review and Perspectives
Top View
Calcimimetic (Cinacalcet, Etelcalcetide) Criteria for Use January 2018
Parathyroidectomy in the Management of Secondary Hyperparathyroidism
Calcimimetics: a New Tool for Management of Hyperparathyroidism and Renal Osteodystrophy in Patients with Chronic Kidney Disease
FDA Accepts Amgen's New Drug Application for Novel Intravenous Calcimimetic Etelcalcetide
The Calcimimetic AMG 073 As a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease
Cinacalcet-Induced Hypocalcemia in a Cohort of European Haemodialysis
Relationship Between Parathyroid Calcium-Sensing Receptor
Calcimimetics Versus Parathyroidectomy for Treatment of Primary Hyperparathyroidism Retrospective Chart Analysis of a Prospective Database
Launch of Parsabiv® Intravenous Injection Syringe for Dialysis, a Calcimimetic Agent in Japan
Discovery of a Calcimimetic with Differential Effects on PTH and Calcitonin Secretion
Gain and Loss of Function Mutations of the Calcium-Sensing Receptor and Associated Proteins: Current Treatment Concepts
Only One Calcimimetic Lowers and Maintains Key Shpt Lab Values with IV Administration You Control1